Overnight Digest: Stocks to look out on August 22
Overnight Digest: Stocks to look out on August 22

Overnight Digest: Stocks to look out on August 22

Geyatee Deshpande Article rating: 5.0

Post SEBI board meet, the stocks to watch out on August 22 inlcude Cadila, V-Mart, P&G Hygiene and Health Care, Reliance Nippon Life asset Management and HDIL.

Biocon hogs limelight as Temasek looks to acquire stake
Biocon hogs limelight as Temasek looks to acquire stake

Biocon hogs limelight as Temasek looks to acquire stake

Anupama Pattanaik Article rating: 5.0

Shares of Biocon rose more than 4 per cent on Wednesday triggered by reports that some domestic and foreign firms are looking to acquire stake in company's subsidiary Biocon Biologics India.

Market Close: Sensex dips 268 pts on hints of slowdown
Market Close: Sensex dips 268 pts on hints of slowdown

Market Close: Sensex dips 268 pts on hints of slowdown

Gayathri Udyawar Article rating: 5.0

The benchmark index BSE Sensex closed down at 37,060.37, down by 267.64 points or 0.72 per cent on Wednesday. The Nifty50 closed at 10,918.70, down by 98.30 points or 0.89 per cent. Bear mode got activated after India's veteran biscuit-maker Parle threatened of job cuts citing economic slowdown.

Who should you choose? Discount or full service broker
Who should you choose? Discount or full service broker

Who should you choose? Discount or full service broker

Gayathri Udyawar Article rating: 3.8

Every investor who is active in the equity market needs to have a demat account and a trading account. With many attractive trading rates advertised by new brokerage firms and the current market volatility, traders as well as investors are looking to cut costs and maximise returns.

Impact of fall in CG Power stock on MF schemes
Impact of fall in CG Power stock on MF schemes

Impact of fall in CG Power stock on MF schemes

Shashikant Singh Article rating: 3.8

CG Power & Industrial Solutions have lost more than 50 per cent of their market value in last one month. Read on to find its impact on MF schemes. 

Zydus Cadila starts phase 2 clinical trial in NAFLD
Zydus Cadila starts phase 2 clinical trial in NAFLD

Zydus Cadila starts phase 2 clinical trial in NAFLD

Apurva Joshi Article rating: 4.5

Zydus Cadila announced on Wednesday that it has initiated a Phase 2 clinical trial for gauging the effect of Saroglitazar Mg in the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in women suffering with polycystic ovary syndrome (PCOS). The EVIDENCES VII trial is currently recruiting patients across several clinical sites in USA and Mexico.

Ten stocks close to their 52-weeks high
Ten stocks close to their 52-weeks high

Ten stocks close to their 52-weeks high

Anupama Pattanaik Article rating: 5.0
The markets on August 21, 2019 opened gap down. BSE Sensex is trading at 37,130.56, down by 197.45 points and the Nifty is trading at 10,944.15, down by 72.85 points.
Alembic Pharma rises on successful inspection at Bioequivalence facility
Alembic Pharma rises on successful inspection at Bioequivalence facility

Alembic Pharma rises on successful inspection at Bioequivalence facility

Amir Shaikh Article rating: 5.0

Gujarat-based pharmaceutical company Alembic Pharma informed the bourses on Wednesday that US Food & Drug Administration (USFDA) has successfully completed inspection at its Bioequivalence facility located at Vadodara.

RSS
First25622563256425652567256925702571Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR